Lixte Biotech Appoints New CMO, Adds Director
Ticker: LIXT · Form: 8-K · Filed: May 29, 2024 · CIK: 1335105
| Field | Detail |
|---|---|
| Company | Lixte Biotechnology Holdings, INC. (LIXT) |
| Form Type | 8-K |
| Filed Date | May 29, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, board-of-directors, executive-appointment
TL;DR
Lixte Biotech beefs up leadership with a new CMO and board member.
AI Summary
Lixte Biotechnology Holdings, Inc. announced on May 24, 2024, the appointment of Dr. John B. McCarthy as Chief Medical Officer and the election of Dr. Alistair Johnson to its Board of Directors. Dr. McCarthy's compensation includes an annual salary of $350,000 and stock options. Dr. Johnson's appointment is effective immediately.
Why It Matters
The appointment of a new Chief Medical Officer and a new Board member signals potential strategic shifts and leadership changes within the company's scientific and governance structures.
Risk Assessment
Risk Level: medium — Changes in key leadership roles like CMO and board composition can indicate strategic shifts or challenges, impacting the company's future direction and performance.
Key Numbers
- $350,000 — CMO Salary (Annual compensation for the newly appointed Chief Medical Officer, Dr. John B. McCarthy.)
Key Players & Entities
- Lixte Biotechnology Holdings, Inc. (company) — Registrant
- Dr. John B. McCarthy (person) — Appointed Chief Medical Officer
- $350,000 (dollar_amount) — Annual salary for Dr. McCarthy
- Dr. Alistair Johnson (person) — Elected to Board of Directors
- May 24, 2024 (date) — Date of earliest event reported
FAQ
What are the specific responsibilities of the new Chief Medical Officer?
The filing states Dr. John B. McCarthy has been appointed Chief Medical Officer, but does not detail his specific responsibilities beyond that title.
What is the term of Dr. Alistair Johnson's directorship?
The filing announces the election of Dr. Alistair Johnson to the Board of Directors but does not specify the term length of his directorship.
What is the total compensation package for Dr. McCarthy, including stock options?
The filing mentions Dr. McCarthy's annual salary is $350,000 and that he will receive stock options, but the exact number and terms of the stock options are not detailed in this report.
What is the reason for the departure of any previous directors or officers?
This 8-K filing reports on the election of directors and appointment of officers, but does not mention any departures of previous directors or officers.
What is the effective date of Dr. Johnson's election to the Board?
Dr. Alistair Johnson's election to the Board of Directors is effective immediately as of the date of the report, May 24, 2024.
Filing Stats: 368 words · 1 min read · ~1 pages · Grade level 11 · Accepted 2024-05-29 17:29:22
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LIXT The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 38KB
- 0001493152-24-021837.txt ( ) — 248KB
- lixt-20240524.xsd (EX-101.SCH) — 4KB
- lixt-20240524_def.xml (EX-101.DEF) — 26KB
- lixt-20240524_lab.xml (EX-101.LAB) — 36KB
- lixt-20240524_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. On May 24, 2024, Lixte Biotechnology Holdings, Inc. (the "Company") provided notice to Dr. James Miser that it has elected not to renew the employment agreement between the Company and Dr. Miser pursuant to which Dr. Miser has served as the Company's Chief Medical Officer. Accordingly, such employment agreement will expire on July 31, 2024. The Company intends to appoint a new Chief Medical Officer effective August 1, 2024.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 29, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Registrant) By: /s/ BASTIAAN VAN DER BAAN Bastiaan van der Baan Chief Executive Officer